MedTrace Logo

Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

NCT01465165 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2017-05-19

No results posted yet for this study

Summary

Several lines of evidence support the existence of an underlying abnormality in brain energy metabolism may play a key role in the biology of mood disorders. The current study utilizes two distinct but complementary imaging techniques, fluorodeoxyglucose (FDG) positron emission tomography (PET) and multinuclear magnetic resonance spectroscopy (MRS), to better understand the nature of these metabolic abnormalities in major depressive disorder (MDD). The investigators hypothesize that individuals with depression will have increased metabolic activity as measured by PET in certain brain regions involved in mood regulation, but that this metabolic activity will be inefficient based on MRS findings. For this study, the investigators will study 10 medication-free, currently depressed participants with recurrent MDD, 10 depressed participants with recurrent MDD currently taking antidepressant medication, and up to 20 healthy control participants matched to depressed participants for age and gender. Depressed and healthy participants will each undergo one PET scan and one MRS scanning session.

Conditions

Sponsors & Collaborators

  • Western Institute for Biomedical Research

    collaborator UNKNOWN

  • University of Utah

    collaborator OTHER

  • Molecular Imaging Program, Huntsman Cancer Institute

    collaborator UNKNOWN

  • Paul Carlson

    lead OTHER

Principal Investigators

  • Paul J Carlson, M.D. · University of Utah

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-15
Primary Completion
2012-06-24
Completion
2012-06-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01465165 on ClinicalTrials.gov